Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 617

1.

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.

Huisman MV, Quinlan DJ, Dahl OE, Schulman S.

Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):652-60. doi: 10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.

2.

Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Nieto JA, Espada NG, Merino RG, González TC.

Thromb Res. 2012 Aug;130(2):183-91. doi: 10.1016/j.thromres.2012.02.011. Epub 2012 Mar 15.

PMID:
22425218
3.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group.

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.

PMID:
21225098
5.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

6.

Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.

Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK.

Thromb Haemost. 2011 Mar;105(3):444-53. doi: 10.1160/TH10-09-0601. Epub 2010 Dec 6.

PMID:
21136019
7.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

8.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

9.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

10.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
11.

Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C.

Thromb Haemost. 2012 Nov;108(5):903-12. doi: 10.1160/TH12-07-0482. Epub 2012 Sep 26.

PMID:
23014668
12.

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees.

Thromb Res. 2010 Sep;126(3):175-82. doi: 10.1016/j.thromres.2010.03.021. Epub 2010 May 15.

PMID:
20434759
13.

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI.

Thromb Haemost. 2009 Jan;101(1):77-85.

PMID:
19132192
14.

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.

Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M.

Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22.

PMID:
23965805
15.

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.

Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR.

J Bone Joint Surg Br. 2009 May;91(5):636-44. doi: 10.1302/0301-620X.91B5.21691. Erratum in: J Bone Joint Surg Br. 2009 Aug;91(8):1120.

PMID:
19407299
17.

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR.

J Bone Joint Surg Br. 2012 Feb;94(2):257-64. doi: 10.1302/0301-620X.94B2.27850.

PMID:
22323697
18.

Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.

Kwok CS, Pradhan S, Yeong JK, Loke YK.

Chest. 2013 Aug;144(2):593-600. doi: 10.1378/chest.12-2634.

PMID:
23519234
19.

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N.

J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9.

PMID:
21385145
20.

Supplemental Content

Support Center